Back to search

H20-HEALTH-Health, demographic change and wellbeing

Bringing a prophylactic Ebola vaccine to licensure

Awarded: NOK 0

The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as: “A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged 65 years), human immunodeficiency virus (HIV)-infected adults, and children aged 1 year.”

Funding scheme:

H20-HEALTH-Health, demographic change and wellbeing

Funding Sources